News | October 25, 2023
Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
The first phase of the hospital with 225 beds built over 1.75 lakh square feet will be commissioned in the next 12 months
The companies will work with investigators to share the results with the scientific community
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
AHH will make an investment of Rs. 600 crore in the company through a mix of primary and secondary infusion
Subscribe To Our Newsletter & Stay Updated
